九品芝麻官

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站

A |     Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。    由你来说：RTX 5080作为英伟达新一代80定位显卡，出现了系列史上首次性能倒退，它的实际性能相比上一代旗舰RTX4090还要低9‑12%。这样一张显卡，为什么依旧被大量玩家买单？     近日海外论坛一则讨论引发大量玩家讨论：RTX5080 作为英伟达新一代 80 定位显卡，出现了系列史上首次性能倒退 —— 它的实际性能相比上一代旗舰 RTX4090 还要低9‑12%。贴主表示，回顾历代80系显卡迭代，GTX1080、RTX3080都能相比上代旗舰实现20%以上的性能跃升，即便是提升偏小的RTX2080，也依旧实现正向增长。唯独RTX 5080，成为80系列里第一次跑不赢上代旗舰的产品。    帖子作者对此颇为不解：性能缩水、售价上调，再加上供电接口的隐患，这样一张显卡，为什么依旧被大量玩家买单？有从RTX3080升级上来的用户表示，虽然价格不菲，但RTX 5080是自己用过体验最好的显卡；从 RTX2070换代的玩家坦言，评测普遍吐槽它性价比拉胯，但对老卡用户而言，这次升级幅度巨大，值得入手。

B |     也有观点直指市场现状：AMD当前消费级旗舰9070 XT性能仅对标RTX5070Ti，在这一档位缺少足够竞争力竞品。即便RTX 5080槽点满满，很多玩家最后会陷入“那我还能买什么”的现实困境。对于20系、30系老卡用户，它依旧是实打实的大幅升级，再加上竞品缺位，造就了这种差评与热卖并存的奇特局面。    你认为为什么RTX5080会如此受欢迎？欢迎在评论区说说你的看法。

Current article:http://9fah3x8.gaxuexiazengpian.pics/emwzsp/sx3fpqe.html

Published on:18:58:37